Proteostasis Therapeutics Inc. CFO James DeTore will leave the company, effective Feb. 10, for personal reasons.

Brett Hagen, the company's controller and principal accounting officer, will assume certain of DeTore's duties on an interim basis, while Proteostasis searches for a permanent CFO.

Hagen previously served as a controller for BIND Therapeutics Inc.